$24 million in CPRIT funding awarded to MD Anderson and related research
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support research, clinical translation and prevention efforts. An additional $15.5 million was awarded to ImmunoGenesis, Inc., which has licensed technologies based on discoveries made by MD Anderson researchers. In total, these projects received nearly 21% of the $114 million...
Combination therapy significantly improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients...